ABSTRACT
There are many types of pancreatic cancer but the most common type is pancreatic adenocarcinoma (accounting for about 85% of cases). Pancreatic cancer is responsible for about 6% of total cancer-related deaths. The global annual rate of occurrence for pancreatic cancer is about 8/100,000 persons [4] . Pancreatic cancer is difficult to diagnose at an early stage, thus 70-80% patients are diagnosed at advanced or metastatic stages of pancreatic cancer [5] . Pancreatic adenocarcinoma has a very poor prognosis, and thus after diagnosis only about 25% of patients survive for 1 year and about 5% patients will live for 5 years. If the cancers have been diagnosed at an early stage, the 5-year survival rate has been seen to increase from 5 to about 20% [1, 6, 7] .
Histone deacetylase inhibitors (HDACi) are an emerging class of anticancer drugs showing prominent antitumor activity by modulating transcriptional events incorporated with cell growth arrest, proliferation, and apoptosis [8] . 
HDACI AND PANCREATIC CANCER
HDACi increased the acetylation of histone and other non-histone proteins, causing alteration in gene expression, angiogenesis, apoptosis, cell-cycle arrest, and metastasis ( Fig. 1) [35] .
Role of HDACi in Suppression of Angiogenesis
HDACi play an important role in regulation of 
Role of HDACi in Apoptosis and Autophagy
HDACi can exert caspase-dependent and -independent apoptosis through both intrinsic [74, 77] .
General Pharmacology of Panobinostat
Panobinostat is a nonselective histone and there was no significant reduction of cell proliferation. They found that panobinostat is more efficient than gemcitabine and increases the potency of gemcitabine in combination therapy [101] . A phase I study was performed to determine the safety and tolerability of panobinostat and gemcitabine in combination These facts clearly provide the evidence for using a combination of panobinostat with MK-1775 in pancreatic tumor cells in preclinical models, and supported the fact that combination therapy should be promoted in the clinical development for this deadly disease.
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